[1] PERTWEE E, SIMAS C, LARSON HJ.An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy[J]. Nat Med, 2022, 28(3): 456-459. [2] THE L.Vaccine scandal and confidence crisis in China[J]. Lancet, 2018, 392(10145): 360. [3] GUZMAN J, CONNELL E, KIKULE K, et al.The WHO global benchmarking tool: a game changer for strengthening national regulatory capacity[J]. BMJ Global Health, 2020, 5(8): e003181. [4] CHODANKAR D.Introduction to real-world evidence studies[J]. Perspect Clin Res, 2021, 12(3): 171-174. [5] HUANG YL, MOON J, SEGAL JB.A comparison of active adverse event surveillance systems worldwide[J]. Drug Saf, 2014, 37(8): 581-596. [6] BAGGS J, GEE J, LEWIS E, et al.The vaccine safety datalink: a model for monitoring immunization safety[J]. Pediatrics, 2011, 127(Suppl 1): 45-53. [7] SCHEIFELE DW, HALPERIN SA, GOLD R, et al.Assuring vaccine safety: a celebration of 10 years of progress with the IMPACT project[J]. Paediatr Child Health, 2002, 7(9): 645-648. [8] XU L, LI N, ZHANG L, et al.Febrile seizures and measles-containing vaccines in China: a self-controlled case series study[J]. Vaccines (Basel), 2021, 9(10): 1073. [9] LIU Z, ZHANG L, YANG Y, et al.Active surveillance of adverse events following human papillomavirus vaccination: feasibility pilot study based on the regional health care information platform in the city of Ningbo, China[J]. J Med Internet Res, 2020, 22(6): e17446. [10] SHANG N, WENG C, HRIPCSAK G.A conceptual framework for evaluating data suitability for observational studies[J]. J Am Med Inform Assoc, 2018, 25(3): 248-258. [11] FDA. Framework for FDA's Real-world evidence program[EB/OL] (2018-12-07)[2022-12-06]. https://www.fda.gov/media/120060/download. [12] NICE. Real-world evidence framework[EB/OL]. (2022-06-23)[2023-01-19]. https://www.nice.org.uk/corporate/ecd9/chapter/overview. [13] Center For Drug Evaluation, National Medical Products Administration. Guidelines (Trial Implementation) for Real World Data Used to Generate Real World Evidence(国家药监局药审中心关于发布《用于产生真实世界证据的真实世界数据指导原则(试行)》的通告)[EB/OL]. (2021-04-13) [2022-12-06]. https://www.cde.org.cn/main/news/viewInfoCommon/2a1c437ed54e7b838a7e86f4ac21c539. [14] ARKSEY H, O'MALLEY L. Scoping studies: towards a methodological framework[J]. International Journal of Social Research Methodology, 2005, 8(1): 19-32. [15] CAI T, LIU LL, YAO XY, et al.Scoping review of active surveillance systems for vaccine safety world-wide[J]. Chin J Prev Med(中华预防医学杂志), 2019, 53(7): 724-730. [16] CARROLL C, BOOTH A, COOPER K.A worked example of “best fit” framework synthesis: a systematic review of views concerning the taking of some potential chemopreventive agents[J]. BMC Med Res Methodol, 2011, 11: 29. [17] CHEN L, WEI JJ, DENG ZJ, et al. Study on the safety evaluation of the use of EV71 inactivated vaccine among the population in Wenzhou[R]. Wenzhou Center for Disease Prevention and Control in Wenzhou, 2020-06-10. [18] ZENG J, TANG T, WANG YJ, et al.Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)[J]. Chin J Prev Med(中华预防医学杂志), 2019, 53(3): 252-257. [19] SHEN LZ, FU Z, PAN XJ, et al.Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)[J]. Chin J Prev Med(中华预防医学杂志), 2019, 53(3): 258-261. [20] PANG H, JIANG Y, ZHANG ZS, et al.Safety monitoring of influenza A (H1N1) vaccination in a district of Shanghai[J]. Journal of Environmental & Occupational Medicine(环境与职业医学), 2011, 28(12): 735-737. [21] CHEN HY, HUANG T, YANG QH.Safety evaluation of 23-valent pneumococcal polysaccharide vaccine's large-scale use in Hubei after listing[J]. Chin J Public Health Management(中国公共卫生管理), 2019, 35(3): 324-327. [22] LI JP, LI RF, L Q, et al. Safety of vaccine for A /H1N1 influenza split virus[J]. J Prev Med Inf(预防医学情报杂志), 2013, 29(7): 572-574. [23] ZHANG WJ, SHI NM, ZHANG YL, et al.Safety of a homemade inactivated enterovirus 71 vaccine in a large population of 6-71 months old children[J]. Chin J Public Health(中国公共卫生), 2019, 35(4): 385-387. [24] ALBOGAMI Y, ALKOFIDE H, ALRWISAN A.COVID-19 vaccine surveillance in saudi arabia: opportunities for real-time assessment[J]. Saudi Pharm J, 2021, 29(8): 914-916. [25] ALI M, CANH DG, CLEMENS JD, et al.The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations[J]. Vaccine, 2003, 21(15): 1681-1686. [26] ALI M, CANH GD, CLEMENS JD, et al.The use of a computerized database to monitor vaccine safety in Viet Nam[J]. Bull World Health Organ, 2005, 83(8): 604-610. [27] BAKER MA, BAER B, KULLDORFF M, et al.Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results[J]. PLoS Med, 2019, 16(7): e1002844. [28] BAKER MA, NGUYEN M, COLE DV, et al.Post-licensure rapid immunization safety monitoring program (PRISM) data characterization[J]. Vaccine, 2013, 31(Suppl 10): K98-K112. [29] BERRUETA M, CIAPPONI A, BARDACH A, et al.Maternal and neonatal data collection systems in low- and middle-income countries for maternal vaccines active safety surveillance systems: a scoping review[J]. BMC Pregnancy Childbirth, 2021, 21(1): 217. [30] BROWN JS, MOORE KM, BRAUN MM, et al.Active influenza vaccine safety surveillance: potential within a healthcare claims environment[J]. Med Care, 2009, 47(12): 1251-1257. [31] CARMONA A, LATORRE TM, MARTINEZ SA, et al.Risk measurement of perinatal and neonatal morbidity characteristics and applicability of gaia case definitions: results and lessons learnt of a hospital-based prospective cohort study in the valencia region (2019-2020)[J]. Int J Environ Res Public Health, 2022, 19(12): 7132. [32] CHEN RT, GLASSER JW, RHODES PH, et al.Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team[J]. Pediatrics, 1997, 99(6): 765-773. [33] CRAWFORD NW, CLOTHIER H, HODGSON K, et al.Active surveillance for adverse events following immunization[J]. Expert Rev Vaccines, 2014, 13(2): 265-276. [34] DAVILA JC, PAYNE DC, ZHANG Y, et al.Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System (DMSS), 1998-2004[J]. Vaccine, 2008, 26(12): 1577-1584. [35] DE LUSIGNAN S, DOS SANTOS G, BYFORD R, et al.Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in English primary care: interim analysis[J]. Adv Ther, 2018, 35(8): 1199-1214. [36] GHOSH RE, CRELLIN E, BEATTY S, et al.How clinical practice research datalink data are used to support pharmacovigilance[J]. Ther Adv Drug Saf, 2019, 10: 2042098619854010. [37] GOLD M, DUGDALE S, WOODMAN RJ, et al.Use of the Australian childhood immunisation register for vaccine safety data linkage[J]. Vaccine, 2010, 28(26): 4308-4311. [38] GUEDEL DS, PETERS IJ, BANDERET F, et al.Smartphone-based active vaccine safety surveillance (SmartVax) at a Swiss adult vaccination clinic - a pilot study[J]. Swiss Med Wkly, 2021, 151(49-50): w30090. [39] SHARAN A, JAHAGIRDAR S, STUURMAN AL, et al.Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: the WHO Global Vaccine safety Multi-Country collaboration project[J]. Vaccine X, 2022, 11: 100160. [40] HABER P, ISKANDER J, WALTON K, et al.Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety[J]. Pediatrics, 2011, 127(Suppl 1): 39-44. [41] HECHTER RC, QIAN L, SY LS, et al.Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project[J]. Vaccine, 2013, 31(7): 1080-1085. [42] HEIJBEL H, JEFFERSON T.Vaccine safety-improving monitoring[J]. Vaccine, 2001, 19(17-19): 2457-2460. [43] LEITE A, THOMAS SL, ANDREWS NJ.Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?[J]. Pharmacoepidemiol Drug Saf, 2018, 27(1): 25-29. [44] MCCARTHY NL, GEE J, WEINTRAUB E, et al.Monitoring vaccine safety using the vaccine safety datalink: utilizing immunization registries for pandemic influenza[J]. Vaccine, 2011, 29(31): 4891-4896. [45] MESFIN YM, CHENG A, LAWRIE J, et al.Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review[J]. BMJ Glob Health, 2019, 4(4): e001065. [46] MESFIN YM, CHENG AC, ENTICOTT J, et al.Use of telephone helpline data for syndromic surveillance of adverse events following immunization in Australia: a retrospective study, 2009 to 2017[J]. Vaccine, 2020, 38(34): 5525-5531. [47] MULLOOLY J, DREW L, DESTEFANO F, et al.Quality of HMO vaccination databases used to monitor childhood vaccine safety. vaccine safety datalink team[J]. Am J Epidemiol, 1999, 149(2): 186-194. [48] NARWANEY KJ, BRESLIN K, ROSS CA, et al.Vaccine adverse events in a safety net healthcare system and a managed care organization[J]. Vaccine, 2017, 35(9): 1335-1340. [49] NASH JQ, CHANDRAKUMAR M, FARRINGTON CP, et al.Feasibility study for identifying adverse events attributable to vaccination by record linkage[J]. Epidemiol Infect, 1995, 114(3): 475-480. [50] NELSON JC, WELLMAN R, YU O, et al.A synthesis of current surveillance planning methods for the sequential monitoring of drug and vaccine adverse effects using electronic health care data[J]. EGEMS (Wash DC), 2016, 4(1): 1219. [51] NGUYEN M, BALL R, MIDTHUN K, et al.The Food and Drug Administration's post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise[J]. Pharmacoepidemiol Drug Saf, 2012, 21(Suppl 1): 291-297. [52] PAYNE DC, ROSE CE, JR, ARANAS A, et al.Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004[J]. Pharmacoepidemiol Drug Saf, 2007, 16(6): 605-611. [53] PLATT R, CARNAHAN RM, BROWN JS, et al.The U.S. Food and Drug Administration's mini-sentinel program: status and direction[J]. Pharmacoepidemiol Drug Saf, 2012, 21(Suppl 1): 1-8. [54] REYBURN R, NAND D, NGUYEN C, et al.Validation of administrative data to estimate vaccine impact: audit of the Fiji hospital admissions electronic database, 2007-2011 & 2014-2015[J]. Vaccine, 2017, 35(47): 6416-6421. [55] SCHWARTZ KL, TU K, WING L, et al.Validation of infant immunization billing codes in administrative data[J]. Hum Vaccin Immunother, 2015, 11(7): 1840-1847. [56] GUILLARD-MAURE C, ELANGO V, BLACK S, et al.Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: the global vaccine safety multi country collaboration initiative[J]. Vaccine, 2018, 36(3): 355-362. [57] STUURMAN AL, SHARAN A, JAHAGIRDAR S, et al.WHO global vaccine safety multi-country collaboration project on safety in pregnancy: assessing the level of diagnostic certainty using standardized case definitions for perinatal and neonatal outcomes and maternal immunization[J]. Vaccine X, 2021, 9: 100123. [58] THOMAS RE, LORENZETTI DL, SPRAGINS W, et al.Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review[J]. Vaccine, 2011, 29(28): 4544-4555. [59] DUSZYNSKI KM, STARK JH, COHET C, et al.Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety[J]. Pharmacoepidemiol Drug Saf, 2021, 30(7): 843-857. [60] TOP KA, CONSTANTINESCU CM, LAFLECHE J, et al.Applicability of the brighton collaboration case definition for seizure after immunization in active and passive surveillance in Canada[J]. Vaccine, 2013, 31(48): 5700-5705. [61] TOP KA, MACARTNEY K, BETTINGER JA, et al.Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia[J]. Euro Surveill, 2020, 25(25): 1900562. [62] TRIFIRO G, COLOMA PM, RIJNBEEK PR, et al.Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?[J]. J Intern Med, 2014, 275(6): 551-561. [63] VERSTRAETEN T, DESTEFANO F, CHEN RT, et al.Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines[J]. Expert Rev Vaccines, 2003, 2(1): 21-29. [64] WATSON G, DODD C, MUNOZ FM, et al.Applicability of the GAIA maternal and neonatal outcome case definitions for the evaluation of adverse events following vaccination in pregnancy in high-income countries[J]. Pediatr Infect Dis J, 2021, 40(12): 1127-1134. [65] FDA. Use of real-world evidence to support regulatory decision-making for medical devices-guidance for industry and Food and Drug Administration staff[EB/OL]. (2018-09-17)[2022-12-06]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices. [66] FDA. Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products[EB/OL]. (2021-12-10)[2022-12-06]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory. [67] LIU D, WU W, LI K, et al.Surveillance of adverse events following immunization in China: Past, present, and future[J]. Vaccine, 2015, 33(32): 4041-4046. [68] YU YL, ZHUO L, MENG RG, et al.Methodology progress and challenges on assessing the appropriateness of real-world data[J]. Chin J Epidemiol(中华流行病学杂志), 2022, 43(4): 578-585. [69] ZHANG HZ, LIU MM, LI L, et al.Study on data governance of the healthcare big data platform based on common data model[J]. J Med Inf(医学信息学杂志), 2022, 43(6): 2-7, 13. [70] BIAN J, LYU T, LOIACONO A, et al.Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data[J]. Journal of the American Medical Informatics Association, 2020, 27(12): 1999-2010. |